Key result
Review evaluates sirolimus-eluting stents in diabetic patients undergoing percutaneous coronary intervention.
Why the study?
Cardiovascular disease in patients with diabetes has unique features and represents about 25% of those treated with PCI, with many having asymptomatic myocardial ischaemia and extensive multivessel disease.
Answers are grounded in this paper and cite their sources.
Diabetes patients comprise ~25% of PCI cases with frequent asymptomatic ischemia and multivessel disease; leaves open optimal risk stratification and revascularization strategies.
Cardiovascular disease is a major consequence of diabetes and is associated with peculiar features in this subgroup of patients, representing roughly 25% of the total population treated with percutaneous coronary interventions (PCIs). A consistent proportion of these patients have asymptomatic myocardial ischaemia, which is a more extensive and diffuse atherosclerotic disease with more prevalent multivessel disease.
No takes yet. Share an insight, caveat, or question.
Maresta et al. (2008) conducted a review in Diabetes. Sirolimus-eluting Stents was evaluated. Sirolimus-eluting stents are discussed in the context of diabetic patients, who represent roughly 25% of the total population treated with percutaneous coronary interventions.
Synapse has enriched 10 related papers. Consider them for comparative context: